We continue our series of posts in the Biologics campaign! Today, we focus on the Bruton’s tyrosine kinase (BTK).
Bruton's tyrosine kinase (BTK) serves as a key non-receptor kinase in oncogenic signaling, exerting an extreme influence on the proliferation and survival of leukemia cells across various B-cell malignancies. It makes this kinase an attractive target for therapeutic intervention.
The study of BTK inhibitors emerges as a promising strategy not only in B-cell malignancies but also in solid tumors. The development and exploration of its inhibitors reveal a paradigm shift in anti-cancer therapy, holding promise for a broader spectrum of malignancies beyond the realm of B-cell disorders.
Got interested? Reach out to us at info@chem-space.com
